RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health. The firm pursues evidence-based investing across public and private markets and provides hands-on support to portfolio companies, including through its Raven healthcare incubator. It relies on deep research via its TechAtlas knowledge engine to identify opportunities and guide value creation from early-stage ideas to commercialization. Since its inception, the firm has deployed capital across multiple rounds and has built a portfolio of hundreds of companies, backed by an ongoing effort to advance drugs, medical devices, diagnostics, and biotech tools. RA Capital manages substantial assets and seeks to invest across stages—from seed to growth—often taking leading roles or co-investing and participating in governance to support management teams. The firm emphasizes impact in healthcare and planetary health, aiming to translate bold ideas into durable improvements in patient care and public health.

SOSV is a global venture capital firm focused on deep-tech investments with an emphasis on ventures addressing human and planetary health. Based in Princeton, New Jersey, it supports startups from pre-seed to growth stages through extensive founder resources and accelerator-style programs that provide access to labs, offices, engineering teams, expert networks, and mentorship to accelerate product development, testing, commercialization, and fundraising. The firm operates dedicated deep-tech facilities, including SOSV SF & NY (IndieBio) and HAX in Newark, and maintains regional activity in San Francisco, New York, Newark, and Princeton. With a portfolio spanning hundreds of companies across multiple countries, SOSV seeks co-investors to join its global network and help scale portfolio companies.

OrbiMed is a global healthcare investment firm, founded in 1989, that invests across the healthcare sector including biopharmaceuticals, medical devices, diagnostics, digital health, and healthcare services. It manages private equity, venture capital, and public equity investments, and provides financing solutions such as private debt and royalty monetization to support the development of new therapies and medical technologies. With a broad, globally distributed team, OrbiMed operates across multiple markets and provides strategic resources to companies from early-stage to growth, aiming to advance scientific innovation and improve patient outcomes.

Invus is a global investment firm with more than four decades of experience partnering with entrepreneurs to transform industries. Since 1985 it has built a patient, long-term capital base and aligns incentives with management to support lasting value creation. The firm manages substantial evergreen capital and operates offices in New York, London, Paris, and Hong Kong, enabling private equity investments, co-investments, and selective opportunities worldwide. It pursues a flexible, non-formulaic approach and focuses on minority and selective control investments across sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education, and medical devices. Invus emphasizes hands-on partnership, strategic guidance, and durable relationships, partnering with market-leading management teams to back growth through private transactions and syndicated financings, with a long-term orientation and capital structures designed to sustain portfolio companies as they scale.

ARCH Venture Partners is a Chicago-based venture capital firm with offices in Seattle that concentrates on life sciences and science-driven startups. Founded in 1986, it partners with scientists and entrepreneurs to bring innovations to market by providing capital, strategic guidance, and access to networks across the company’s lifecycle. The firm emphasizes translational work from academic research and national laboratories, and has raised more than $3 billion across multiple funds and invested in more than 150 companies, highlighting a hands-on approach to catalyzing discovery and execution in the life sciences sector.

The European Innovation Council is a European Commission initiative that supports Europe’s deep-tech innovators, researchers, and startups. It funds breakthrough research and technology transfer projects, and delivers equity-like investments through the EIC Fund, as well as prizes and acceleration services to help teams scale. The council also co-invests with private investors in early-stage ventures and places emphasis on high-impact technologies with ESG relevance. Established in 2018 and headquartered in Brussels, it concentrates on deep-tech sectors including defence and dual-use technologies, while promoting international collaboration and market access for awardees. It aims to strengthen Europe’s innovation ecosystem by sharing data, hosting events, publishing insights, and fostering partnerships that accelerate the journey from lab to market.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, with offices in Asia. It operates a multi-strategy platform spanning venture capital, growth equity, private equity including buyouts, and public equity, and invests across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm focuses on opportunities in the United States and China and maintains a track record of backing healthcare companies through multiple funding stages, including IPOs and strategic acquisitions. Assets under management are reported in the mid-to-high billions, approximately 5.8 to 6.1 billion, across several funds.

Samsara BioCapital is a biotech-focused venture capital and investment advisory firm based in Palo Alto, California, founded in 2016. The firm seeks to invest in biotechnology and healthcare companies across the United States, aiming to advance transformative therapeutics through scientific collaboration and strategic partnerships. It emphasizes assembling multidisciplinary teams of scientists, physicians, drug developers, and business leaders to accelerate therapeutic breakthroughs and create innovative medicines. The firm also operates as a registered investment adviser.

Sofinnova Partners is an independent venture capital firm based in Paris, France, founded in 1972, that invests in life sciences from seed to growth stages. It backs start-ups, corporate spin-offs and occasionally turnaround situations, focusing on biopharmaceuticals, biotech, medical devices, digital medicine, and related healthcare and sustainability innovations. The firm acts as a lead or cornerstone investor and frequently serves as the first institutional investor in Series A rounds, taking board seats and supporting portfolio companies from formation through exit to drive long-term value.

Forbion is a global venture capital firm based in Naarden, Netherlands, specializing in investments in biotech, life sciences, and sustainable technologies. With two decades of experience, it backs both early-stage and growth-stage companies across Europe and North America, providing capital and strategic guidance to help translate scientific advances into therapies, diagnostics, and related health tech. The firm maintains a multi-fund platform and emphasizes responsible investing, including environmental, social, and governance considerations. Forbion collaborates with portfolio companies to support development and commercialization of innovative products that address human health and planetary health needs.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and health science startups. Founded in 2009 and based in Cambridge, Massachusetts, with an office in San Francisco, the firm leverages a long-standing leadership team and a broad network to provide hands-on mentorship, strategic guidance, and resources such as shared laboratory space to portfolio companies. It emphasizes collaboration, innovation, and support for founders from diverse backgrounds, helping startups advance through research, development, and early commercial stages in the life sciences sector.

TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines in the healthcare sector. It manages a private portfolio of investments and supports companies developing better treatment options for patients, including opportunities in private and public entities led by entrepreneurs. With teams in Palo Alto and New York City, the firm emphasizes rigorous scientific evaluation and portfolio management to accelerate breakthroughs in pharmaceutical solutions and health technology across the United States and Europe.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on the biotechnology and life sciences sectors. It invests in public and pre-IPO biotechnology companies and emphasizes partnering with management teams, offering time, expertise, and a broad network in addition to capital. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, providing strategic guidance and resources to portfolio companies.

Versant Ventures is a California-headquartered venture capital firm focused on the healthcare sector, including medical devices, biotechnology and pharmaceuticals. Founded in 1999, it takes a hands-on approach to building companies across the life sciences spectrum, supporting early- and later-stage ventures from discovery to commercialization. The firm operates globally with multiple research and collaboration channels, including discovery engines across several locations and partnerships with academic institutions to accelerate translational science. Its portfolio has delivered numerous successful exits, with more than 65 portfolio companies achieving acquisitions or IPOs.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage investments in biotechnology and life sciences, with additional focus on technology companies. It partners with life science entrepreneurs to translate scientific discoveries into medicines and related diagnostics, often leading seed or Series A rounds and providing strategic guidance and board involvement. Founded in 1980, Atlas Venture has organized multiple funds and operates with dedicated Life Sciences and Technology teams to manage portfolio companies across the United States and Europe. Its portfolio emphasizes biopharmaceuticals, therapeutics, and medical technologies, along with software and data-driven technologies that support life science commercialization.

Deerfield Management is a New York-based healthcare investment firm that advances human health through investment, research, and philanthropy. It manages investment strategies across public and private markets in biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and healthcare services, and supports early-stage innovation through strategic partnerships and dedicated facilities that foster scientific research and drug discovery. The firm operates a philanthropic foundation focused on education, healthcare access, and initiatives aimed at improving health outcomes.

Logos Capital is an investment firm based in San Francisco that focuses on biotechnology. Founded in 2019, the company combines data analytics with scientific and clinical expertise to identify transformative therapies and opportunities in healthcare. Its multidisciplinary team spans biotechnology, medicine, and data science, and it uses a proprietary Logos Analytics platform to model clinical data, informing diligence and investment decisions. Logos Capital seeks long-term value by providing capital and strategic guidance to companies advancing innovative therapies, applying rigorous risk management and comprehensive analysis of clinical, regulatory, operational, and commercial factors. The firm evaluates opportunities across private and public biotechnology companies, aiming to generate meaningful returns through disciplined research and evidence-based investing.

Alumni Ventures is a venture capital firm that broadens access to venture and private market investments for accredited investors, including alumni networks, by enabling co-investment alongside leading VC firms. It offers investment funds, investing clubs, portfolio opportunities, and educational resources through its AV Academy, and provides support to startup founders. The firm emphasizes transparency with access to due diligence materials and live discussions, and seeks to build a diversified portfolio through collaborative investing. Headquartered in Manchester, New Hampshire, it operates with offices in New York, Boston, Menlo Park, Chicago, London and Tokyo to reach a broad investor base.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. The firm focuses on technology and healthcare companies across multiple stages, from seed to growth and public offerings, and aims to support entrepreneurs with more than capital by providing domain expertise, operational guidance, and assistance with product development and market expansion. NEA works with founders to navigate technical challenges and changing economic environments, leveraging a long track record of helping portfolio companies scale. Its investment scope spans software, consumer technology, medical devices, life sciences, healthcare information technology, energy technology, and related sectors, with a global footprint that includes activity in the United States, Asia, and Brazil. Beyond financing, NEA emphasizes long-term partnerships, sharing industry insights and resources with portfolio companies, and leveraging a network of venture partners, executives, and professionals to support growth and strategic initiatives. Since its founding, the firm has supported numerous portfolio companies through IPOs and acquisitions.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic guidance to technology startups across stages. It invests in companies across sectors such as artificial intelligence, healthcare, climate tech, digital health, sustainability, and consumer technology, with emphasis on bold, innovative business models and science-driven approaches. The firm manages multiple funds and takes an active, long-term partnership stance, offering operational support and strategic advice to help build durable companies. Based in Menlo Park, California, Khosla Ventures seeks to back entrepreneurs solving complex problems in AI, energy, biotech, software, and related fields, often funding early-stage ventures as well as opportunities at later stages.

Omega Funds is a Boston-based venture capital firm focused on investing in life sciences and healthcare companies across North America and Western Europe. Founded in 2004, the firm targets opportunities in oncology, immunology, rare diseases, precision medicine, digital health, cybersecurity, and software-as-a-service, providing capital and strategic support to entrepreneurs and founders. With emphasis on early-stage and growth-oriented opportunities, Omega Funds leverages an experienced team, a broad industry network, and a track record of helping portfolio companies advance products to patients and achieve strategic exits through public listings or acquisitions. The firm positions itself as a value-added investor, aligning scientific advancement with business development to drive meaningful clinical and commercial outcomes in the life sciences space. It operates as a registered investment adviser with international exposure across North America and Western Europe.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with an emphasis on early-stage drug discovery and long-term value creation. Founded in 2007, it supports companies from seed financing to later-stage development through an edge-to-edge investment approach across multiple funds, and it prioritizes deep scientific principles, hands-on mentoring for CEOs, and building strong, scientifically driven teams. Over its two-decade history, The Column Group has nurtured numerous biotech ventures and delivered substantial returns for its partners, while typically investing about $15–$30 million per deal in the United States across healthcare, oncology, drug discovery, and related sectors.

BioVenture is a China-based healthcare investment firm anchored in Suzhou's bioBAY ecosystem, specializing in early- and growth-stage life sciences companies. Since 2013, it has supported more than 200 portfolio companies across new drug discovery, medical devices, diagnostics, precision medicine and medical services, with a network built on BioBAY that enables post-investment value-add and rapid growth. The company is known for a seasoned investment team, strong industry resources, and world-class scientific advisors, and has backed multiple portfolio companies that have progressed to public listings on major markets. BioVenture emphasizes global reach, robust deal flow, and a commitment to helping portfolio companies scale through strategic guidance and operational support.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

EcoR1 Capital is a San Francisco-based venture capital firm focused on supporting early-stage biotechnology companies developing innovative therapies. The firm seeks to back entrepreneurs driving therapeutic innovation and positions itself as a strategic partner to navigate drug discovery and development, leveraging scientific curiosity and a deep biotech background to identify valuable opportunities in biotech and help advance new medicines.

IMM Private Equity is an independent private equity firm based in Seoul, South Korea, specializing in growth capital, significant minority investments, and middle-market buyouts. It pursues Korea- and Asia-focused opportunities, taking an active role in portfolio companies to drive value through strategic guidance and operational improvements across sectors such as manufacturing, information technology, internet, leisure, retail, and cultural contents.

SR One is the corporate venture capital arm of GlaxoSmithKline and operates as a transatlantic biotechnology venture firm that invests globally in emerging life science companies pursuing innovative science to significantly improve medical care. Founded in 1985, it is based in Redwood City, California, with a London presence that provides geographic reach and regional expertise. The firm uses a back-and-build investment approach, partnering with founders to back companies with strong fundamentals, clear development plans, and novel approaches to disease treatment, to accelerate the translation of scientific breakthroughs into medicines. Since inception, SR One has invested about 800 million in more than 180 companies.

HBM Healthcare Investments is a Switzerland-based investment firm focused on globally diversified investments in private and public healthcare companies. Founded in 2001 and headquartered in Zug, it concentrates on sectors including human medicine, biotechnology, medical technology and diagnostics, maintaining a portfolio across private holdings, public equities and funds. The company seeks exposure to healthcare growth drivers such as medical innovation, rising access to care and demographic trends, and operates with a global reach to identify opportunities across mature and emerging companies.

Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with offices in San Francisco and Cambridge. Founded in 2018, it provides growth capital to companies operating in life sciences, diagnostics, digital health, health tech, therapeutics, medical devices and related technology-enabled sectors, supporting ventures that advance scientific innovation and improve healthcare outcomes.

Flagship Pioneering is a Cambridge, Massachusetts based venture capital firm that conceives, creates, resources, and grows first-in-category ventures to transform human health, biology, medicine, energy, and sustainability. The firm uses science-driven entrepreneurship to envision alternative futures and drive transformational outcomes through an evolutionary methodology. It combines innovative capacity, entrepreneurial leadership, and capital management in a single enterprise that systematically builds companies in health technology, biotechnology, life sciences, and agriculture. Flagship Pioneering emphasizes its people, process, and values to create impactful companies with a focus on transformative science and technology. Its approach includes partnerships with large organizations and industry collaborators such as AWS, Pfizer, GSK, IQVIA, and Thermo Fisher Scientific to accelerate innovation, and its portfolio includes Moderna, Tessera Therapeutics, Generate Biomedicines, Inari Agriculture, Quotient Therapeutics, and Lila Sciences. It is committed to creating value by inventing and building companies addressing significant challenges in healthcare and sustainability.

Merck & Co. is a global, research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines and vaccines to address unmet medical needs worldwide. The company concentrates on oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology, leveraging data science and AI to advance its pipeline. Its immuno-oncology platform, led by Keytruda, is a major growth driver, while its vaccines business includes pediatric vaccines and Gardasil for HPV. Merck also pursues patient access through assistance programs and engages in sustainability initiatives such as Merck for Mothers. With a history spanning more than a century, the company maintains a global manufacturing and commercial footprint across pharmaceuticals, vaccines, and animal health, guided by scientific innovation, disciplined R&D, and a commitment to improving health outcomes worldwide.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in the United States, the firm invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early discovery to commercial stage, with a focus on precision medicine and transformative medical advancements. Boxer Capital combines fundamental research with a multidisciplinary analysis of scientific, clinical, regulatory, and commercial factors to translate innovation into opportunity. It pursues opportunities across the full drug lifecycle and provides financial capital and strategic guidance to portfolio companies. The firm notes partnerships with companies such as Mirati Therapeutics and Pandion Therapeutics as examples of its collaborative approach.

Gaingels is a venture investment syndicate focused on LGBTQ+ founders and inclusive leadership. It invests in companies with LGBTQ+ founders and C-suite leaders across stages and helps established firms build diverse teams and inclusive boards. The network is global, with a portfolio of over 130 companies and about 70 million dollars deployed. Gaingels emphasizes supportive founder relationships and leverages a broad network of co-investors to promote positive social change through business and inclusive leadership.

DCVC, also known as Data Collective, is a venture capital firm founded in 2011 and based in Palo Alto, California. It concentrates on deep tech and science-driven startups, investing in early-stage companies across artificial intelligence, exascale computing, climate, engineering, materials science, robotics, space, water, biology, defense, security, and related technologies. The team emphasizes scientific and engineering expertise, often backing ventures led by researchers and technologists to translate fundamental discoveries into scalable businesses. With activity across the United States, DCVC aims to support founders pursuing data-driven, automated, and high-impact solutions that address large global challenges.

Kurma Partners is a Paris-based private equity and venture capital firm established in 2009 that concentrates on healthcare and biotechnology investments across Europe, providing capital from early stages through development and growth. The firm focuses on financing therapeutic and medical innovations and maintains close collaborations with leading academic research institutions and hospitals to translate discoveries into medicines and medical devices. It manages a suite of funds, including Kurma Biofund I, Kurma Biofund II, Kurma Biofund III, Kurma Diagnostics and Kurma Growth Opportunities Fund, and partners with other investors to support companies from creation to expansion.

Mitsubishi UFJ Capital is a Tokyo-based venture capital firm that backs startups at seed and development stages in Japan, with a focus on life sciences, information technology, and high-technology sectors such as AI, SaaS, electronics, biotech, fintech, and healthcare. Founded in 1974, the firm pursues early-stage and growth opportunities through a diversified portfolio and active deal flow, often engaging in co-investments with other investors to build value for portfolio companies. It concentrates on opportunities that have relevance to the Japanese market and supports founders in fundraising, product development, and scaling strategy.

Legend Capital is a Beijing-based venture capital firm established in 2001 as a subsidiary of Legend Holdings Ltd. It concentrates on early-stage and growth investments in China, with a focus on information technology, telecommunications, media, enterprise services, consumer sectors, healthcare, and intelligent manufacturing. The firm manages multiple funds and supports portfolio companies with resources for business development, market expansion in China, and brand building to help them scale. Operating from Beijing with additional offices in Shanghai, Shenzhen, and Hong Kong, Legend Capital has backed a broad range of Chinese technology and growth companies across various stages, aiming to drive long-term value creation through professional management and technology-driven growth.

MPM BioImpact is a venture capital firm based in Boston that invests in biotechnology, healthcare, and life sciences companies across the entire drug development process, from early research to public markets. With over 30 years of experience, the firm backs private and public companies aiming to translate scientific breakthroughs into life-saving medicines. It emphasizes building and supporting ventures that improve patient outcomes, drawing on a team of industry experts and entrepreneur partners. Its portfolio includes Orna Therapeutics, developing circular RNA medicines, Aktis Oncology, pioneering radio-pharmaceuticals, and Reunion Neuroscience, advancing psychedelic-inspired therapies for mental health. MPM BioImpact has demonstrated a track record of backing companies that produce FDA-approved drugs, engage in M&A activity, and pursue initial public offerings, reflecting a continued commitment to advancing innovative therapies.

Third Rock Ventures is a venture capital firm founded in 2007 and headquartered in Boston, Massachusetts, with additional offices in San Francisco. It focuses on life sciences and healthcare, including biotechnology, medicine, drugs, devices, diagnostics, therapeutics, and related information technology. The firm invests in early-stage and startup companies with high growth potential and transformative potential in healthcare. It typically leads rounds and pursues active involvement in portfolio companies, including strategic collaborations and hands-on management where appropriate, to help build companies from concept to market. Its approach emphasizes developing patient-centered solutions and advancing therapies and technologies across multiple therapeutic areas, including oncology, autoimmune diseases, and gene therapy. The firm generally concentrates its investments in U.S.-based life sciences companies and seeks to partner with entrepreneurs to accelerate development of medicines, diagnostics, and medical technologies.

Lux Capital is a venture capital firm based in New York City and Silicon Valley that backs science-driven startups in sectors such as artificial intelligence, biotechnology, advanced materials, space, energy, biochemistry, electronics, infrastructure, and aerospace. The firm invests across seed, early-stage, and growth rounds and takes an active role in helping entrepreneurs translate scientific research into scalable businesses, providing capital alongside strategic input on product development and long-term positioning. Its team evaluates opportunities on the strength of underlying science, potential industry impact, and feasibility over extended horizons, and has a track record of building more than 20 portfolio companies from scratch, aiming to connect portfolio companies with deep insight and industry leadership.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 that focuses on seed- and early-stage investments in life sciences, healthcare, and related technologies. The firm backs companies in biopharmaceuticals, drug delivery, medical devices, life science instruments, and digital health, primarily in the United States. It maintains offices in San Francisco and Boston and manages several funds, including recent vehicles with about $750 million in capital. The firm emphasizes a hands-on approach through an internal program to discover, incubate, and fund breakthrough science by partnering with academics and entrepreneurs, helping portfolio companies translate scientific advances into clinical impact.

EIT Food is a European initiative supported by the European Union that aims to transform the food system through innovation and collaboration. It unites industry, education, and research partners to accelerate healthier diets, resilient agriculture, and sustainable production, with focus areas including Healthier Lives Through Food, Food System Resilience, Net Zero Food System, Protein Diversification, Resilient Agriculture, and Agri-food Biotech. The organization promotes open calls for innovation, connects stakeholders across the entire food system, and seeks to mobilize funding and bring new ideas to market. Through its mission, it aims to reduce CO2 emissions, equip farmers with new skills, and foster a dynamic innovation community across Europe, ultimately reshaping how food is produced, distributed, and consumed by 2035.

Catalio Capital Management is a New York-based investment firm focused on biomedical technology and life sciences. The firm invests across the full lifecycle of healthcare companies, including private equity, private credit, and public equity, and employs a long-biased, fundamental, bottom-up approach with opportunities across venture capital, structured investments, co-investments, and public markets. It collaborates with a network of scientist-entrepreneurs and venture partners to source deals, support portfolio companies, and guide opportunities through IPOs, mergers and acquisitions, and debt repayments. As of October 2025, the firm manages about $2 billion in assets, with a team of over 40 employees and 45 venture partners. The business concentrates on drugs, AI-enabled diagnostics, and other life sciences technologies across various stages of development, seeking to build category-defining platforms.

Takeda is a global biopharmaceutical company focused on the research, development, and commercialization of innovative therapies. Its five core therapeutic areas—oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies—account for more than 80% of revenue. The company operates across the United States, Europe, Japan, and other regions, with a diversified geographic footprint that supports access to medicines worldwide. Takeda emphasizes patient-centric innovation, robust R&D capabilities, and external collaborations to advance clinical proof of concept and bring therapies to patients. The company pursues responsible corporate governance and climate-ready healthcare initiatives, and seeks to address unmet medical needs through sustainable practices and partnerships with researchers, healthcare providers, and patient communities. Takeda's portfolio includes prescription medicines and related therapies, with ongoing efforts to expand access, improve outcomes, and drive value across its core areas.

Leaps by Bayer is the corporate venture arm of Bayer, investing in paradigm-shifting advances in life sciences. It focuses on biotechnology, agriculture, and other scientific breakthroughs to accelerate transformative technologies that could improve health care and agricultural sustainability. Established in 2015 and based in Leverkusen, Germany, Leaps pursues investments that aim to shift paradigms from symptom treatment to prevention or cure and to support innovations that address a growing population's needs while restoring the planet.

Vida Ventures is a life sciences venture capital firm founded in 2017 by scientists, physicians, entrepreneurs, and investors. It aims to transform biomedical innovations into therapies that improve patient lives. The firm builds and funds companies across biomedical sectors, with a focus on oncology, immunology, neuroscience, and infectious diseases. It collaborates with established pharmaceutical companies to advance promising drug candidates and technologies. Notable investments include Third Arc Bio, Scorpion Therapeutics, and InduPro. The firm emphasizes patient-centricity, integrity, entrepreneurship, boldness, humility, and collaboration, and has a track record of creating companies and delivering value.

Seventure Partners is a Paris-based venture capital firm founded in 1997 that focuses on digital technologies and life sciences. It pursues early to growth-stage investments across a broad portfolio including biotech, healthcare, nutrition, microbiome, medical devices and digital health, as well as technology sectors such as B2B software, fintech, retail tech, cybersecurity, IoT, and blue economy activities like sustainable aquaculture, biopolymers and recycling. The firm also backs sports, wellbeing and related digital solutions as part of its tech and life sciences scope. Seventure provides capital together with hands-on expertise, networks and operational support to help portfolio companies scale. With about one billion euros under management and offices in Paris with a global reach across Europe, North America, and Asia-Pacific, it backs entrepreneurs from early to growth stages and aims to accelerate growth and value creation for tomorrow's European leaders.

Commodore Capital is a New York-based venture capital firm focused on biopharmaceuticals. Founded in 2019, the firm concentrates on early-stage companies developing innovative therapies, with emphasis on genetic medicines and cellular therapies, during a period of rapid scientific advancement translating into clinical breakthroughs. It aims to be a supportive partner to smaller biopharmaceutical companies as they develop and deliver new medicines to patients globally.